Torsten Hechler

Schriesheimer Str. 101
Ladenburg, BW 68526, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 20 publications

Physicochemical and Metabolic Optimization of NAMPT Inhibitors Enables Effective Antibody-Drug Conjugates for Liquid and Solid Tumors.

Physicochemical and Metabolic Optimization of NAMPT Inhibitors Enables Effective Antibody-Drug Conjugates for Liquid and Solid Tumors.

Journal: ACS bio & med chem Au

Published: March 04, 2026

pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma.

pH-Dependent Microenvironmental Ionic Signaling in Pancreatic Ductal Adenocarcinoma.

Journal: Acta physiologica (Oxford, England)

Published: December 12, 2025

Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy.

Amanitin-Based Fc-Small Molecule-Drug Conjugates with Noncleavable Linker: A Novel Therapeutic Strategy for Prostate Cancer Targeted Therapy.

Journal: Molecular cancer therapeutics

Published: October 23, 2025

Site-Specific Modification of Native IgGs with Flexible Drug-Load.

Site-Specific Modification of Native IgGs with Flexible Drug-Load.

Journal: Chembiochem : a European journal of chemical biology

Published: June 12, 2024

Novel Amanitin-Based Antibody-Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer.

Novel Amanitin-Based Antibody-Drug Conjugates Targeting TROP2 for the Treatment of Pancreatic Cancer.

Journal: Molecular cancer therapeutics

Published: April 16, 2024

ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.

ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.

Journal: Cancer research communications

Published: March 22, 2024

Design, Synthesis, and Biochemical Evaluation of Alpha-Amanitin Derivatives Containing Analogs of the trans-Hydroxyproline Residue for Potential Use in Antibody-Drug Conjugates.

Design, Synthesis, and Biochemical Evaluation of Alpha-Amanitin Derivatives Containing Analogs of the trans-Hydroxyproline Residue for Potential Use in Antibody-Drug Conjugates.

Journal: Chemistry (Weinheim an der Bergstrasse, Germany)

Published: April 16, 2021

Enhancing the Pharmacokinetics and Antitumor Activity of an α-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain.

Enhancing the Pharmacokinetics and Antitumor Activity of an α-Amanitin-Based Small-Molecule Drug Conjugate via Conjugation with an Fc Domain.

Journal: Journal of medicinal chemistry

Published: March 23, 2021

AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.

AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53.

Journal: Gastroenterology

Published: January 06, 2021

Targeted immunotherapy for HER2-low breast cancer with 17p loss.

Targeted immunotherapy for HER2-low breast cancer with 17p loss.

Journal: Science translational medicine

Published: May 08, 2020

HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells.

HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells.

Journal: Molecular cancer therapeutics

Published: April 10, 2020

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.

CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma.

Journal: Blood advances

Published: December 13, 2019

Showing 1-12 of 20

Last Updated: 09/26/2026